A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects with Tourette Syndrome

Administered By

Awarded By

Contributors

Start/End

  • January 24, 2018 - December 31, 2019